pharmaphorum

OCTOBER 26, 2022

But Giacomo Chiesi, head of Chiesi Global Rare Diseases, thinks of his 6,000-person company as a family business. And just as a family business thrives on its connection to the community, Chiesi is committed to connecting to the global patient community. Caring for a global community. This sets a high bar,” he says. “It

Development 96

Development Trials Marketing Life Science 96

Pharma Marketing Network

JUNE 10, 2020

But now we’re seeing innovations hitting the enterprise, we’re seeing more and more big corporations, particularly our client’s base pharma and hospital systems, looking at new things that are happening that will truly help them transform their business. I’ll be your host today. He’s known industry-wide.

Marketing 52

Marketing Clinical Trials Clinical Trials Nurses 52

Pharma Marketing Network

JUNE 10, 2020

But now we’re seeing innovations hitting the enterprise, we’re seeing more and more big corporations, particularly our client’s base pharma and hospital systems, looking at new things that are happening that will truly help them transform their business. I’ll be your host today. He’s known industry-wide.

Marketing 40

Marketing Clinical Trials Clinical Trials Nurses 40

XTalks

JUNE 12, 2023

This article takes a comprehensive look at the top 10 medical device companies that are leading the charge in this rapidly evolving field. Join us as we explore the inspiring journey and significant contributions of these top 10 medical device companies. 2022 R&D Spend: Medtronic’s R&D expenses were $2.75

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

pharmaphorum

FEBRUARY 16, 2021

In this feature, Grünenthal’s Florent Eduoard and Kate Hurtig outline their principles for a new pharmaceutical marketing model. . This could be through a wise quote cracked in a meeting to give the right gravitas to any challenged proposal. ‘If If Maslow said so, who dares challenge my proposal?’.

Marketing 106

Marketing Big Data Production Pharma Companies 106

The Pharma Data

JULY 6, 2021

At its Investor Update on 23 June, GSK set out new ambitions for patients and a step-change in growth and performance for shareholders. Major progress has been achieved to improve performance, strengthen R&D productivity, enhance commercial execution, and to streamline GSK’s portfolio and cost base.

Sales 52

Sales Vaccination Vaccine Production 52